2015 Therapeutic Proteins

Current list of FDA-approved MABs and fusion proteins

  1. the same target may be active in different diseases, therefore the same drug (or a different drug targeting the same protein or process) may be used to treat different diseases
    • e.g.
      • VEGF in colon cancer and macular degeneration
      • CTLA4 in psoraisis and rheumatoid arthritis

  2. different antibodies (humanized vs. chimeric) may be used against the same target (usually because different drug companies use different approaches to design the drugs)
    • e.g. basiliximab and daclizumab target the interleukin 2 receptor (CD25) and are used in organ transplantation

  3. cytotoxic agents can be used to increase efficacy
    • e.g., ibritumomab and tositumomab vs. rituximab in cancer treatment

*** THIS TABLE IS FOR GENERAL REFERENCE, DON'T MEMORIZE THIS LIST FOR THE TEST! ***

You will hear more about individual drugs in subsequent lectures (you can learn the names and targets then!)

ANTIBODIES
Disease
Drug
Target
Cancer treatment

Alemtuzumab (Campath)

CD52 (B-cell chronic lymphocytic leukemia)

Bevacizumab (Avastin)

VEGF (colon cancer)

Cetuximab (Erbitux)

EGFR (colon cancer)

Edrecolomab (Panorex)

17-1A (colon cancer)

Gemtuzumab ozogamicin (Mylotarg)

CD33 (acute myeloid leukemia)
ozogamicin is cytotoxic

Ibritumomab tiuxetan (Zevalin)

CD20 (B-cell non-Hodgkin’s lymphoma)
yttrium 90 labelled

Ofatumumab (Arzerra) CD20 (B-cell non-Hodgkin’s lymphoma)
Panitumumab (Vectibix) EGFR (colon cancer)

Rituximab (Rituxan)

CD20 (B-cell non-Hodgkin’s lymphoma)

Tositumomab (Bexxar)

CD20 (B-cell non-Hodgkin’s lymphoma)
iodine 131 labelled

Trastuzumab (Herceptin)

HER2 (breast cancer)

Cancer diagnosis

Arcitumomab (CEA-Scan)

Carcinoembryonic antigen (colorectal cancer)

Capromab pendetide (Prostascint)

Prostate specific antigen (prostate cancer)

Nofetumomab (Verluma)

40-kD antigen (small cell lung cancer + others)

Satumomab (OncoScint)

TAG-72 (colorectal and ovarian adenocarcinomas)
Organ transplantation

Basiliximab (Simulect)

Interleukin 2 receptor (CD25)

Daclizumab (Zenapax)

Interleukin 2 receptor (CD25)

Muromonab-CD3 (Orthoclone OKT3)

CD3
Crohn's disease

Certolizumab (Cimzia)
Infliximab
 (Remicade)

TNFα

Natalizumab (Tysabri)

Integrin 4
Rheumatoid arthritis

Adalimumab (Humira)
Certolizumab (Cimzia)
Golimumab
(Simponi)
Infliximab  (Remicade)

TNFα

Tocilizumab  (Actemra) IL-6 receptor
Asthma
Omalizumab (Xolair)

IgE

Coronary heart disease and stroke

Abciximab (ReoPro)

Glycoprotein IIb/IIIa receptor

Macular degeneration

Bevacizumab (Avastin)
Ranibzumab
 (Lucentis)

VEGF
Multiple sclerosis
Natalizumab (Tysabri)
Integrin 4
Psoraisis Efalizumab (Synagis) Leukocyte function antigen 1
(LFA-1; CD11a)
Ustekinumab (Stelara) IL-12 and IL-23

Palivizumab (Synagis)

Antigenic site of the F protein of RSV

Systemic lupus erythematosus

Ruplizumab (Antova)

CD40L

Osteoporosis
(and metastasized solid tumours)
Denosumab (Prolia, Xgeva)
Rank ligand
Eculizumab
Complement protein C5
FUSION PROTEINS
Psoriasis

Alefacept (Amevive)
Abatacept (Orencia)

CTLA4
Rheumatoid arthritis

Abatacept
 (Orencia)

CTLA4

Etanercept
 (Enbrel)
Tumor necrosis factor receptor
Cryopyrin-associated periodic syndromes Rilonacept
 (Ontek)
IL-1
Cancer
Denileukin diftitux
 (Ontek)
IL-2 (T-cell lymphoma)
Email: Dr. Janet Fitzakerley | ©2015 University of Minnesota Medical School Duluth | Last modified: 27-apr-15 1:11 PM